Medicine - Xagena

Medicine

News

Drugs

Xapedia

Farmaci

Farmacia

Medicina

Specialità

Procysbi for management of nephropathic cystinosis : FDA approved

Diclegis for pregnant women with nausea and vomiting: FDA approved

Xofigo for advanced prostate cancer, FDA approved

ARISTOTLE subanalysis: efficacy of Apixaban in patients with non-valvular atrial fibrillation

Positive CHMP opinion in EU for once-daily, oral Aubagio to treat relapsing-remitting multiple sclerosis

Rhabdomyolysis without the presence of neuroleptic malignant syndrome suspected of being associated with the use of Risperidone

Tecfidera as a first-line oral treatment for relapsing forms of multiple sclerosis

Botulism antitoxin for use in neutralizing all seven known botulinum nerve toxin serotypes, approved by FDA

Canagliflozin, a SGLT2 inhibitor, for the treatment of adults with type 2 diabetes

HIV patients co-infected with hepatitis C virus: Faldaprevir combined with Pegylated Interferon and Ribavirin

Psoriasis: oral Apremilast achieves statistical significance for the primary endpoint of PASI-75 in the ESTEEM 1

Ultra long-acting beta-adrenoceptor agonist: Olodaterol for maintenance treatment of COPD, recommended for approval

Anemia drug: Omontys linked to serious and fatal hypersensitivity reactions

PAVES trial: Pegfilgrastim reduces the incidence of febrile neutropenia in patients with colorectal cancer receiving FOLFOX or FOLFIRI and Bevacizumab

Peginterferon beta-1a in relapsing-remitting multiple sclerosis: positive results from ADVANCE trial

Treatment of diabetes in adults: Tresiba and Ryzodeg approved in European Union

FDA has approved three Alogliptin-based therapies for type 2 diabetes: Nesina, Oseni and Kazano

2013 - DECISION Trial: Sorafenib improves progression-free survival in patients with radioactive iodine refractory differentiated thyroid cancer

Post-menopausal osteoporosis: Odanacatib, Cathepsin K inhibitor, increases BMD following prior Alendronate treatment

Hepatotoxicity remains an important safety concern for all antiandrogen drugs

Elotuzumab in patients with previously-treated multiple myeloma

Seebri Breezhaler as once-daily maintenance treatment for COPD in the European Union

Afinitor for advanced breast cancer, FDA approved

FDA has approved new indication for Eltrombopag: supportive care for patients with thrombocytopenia with chronic hepatitis C to allow the initiation and maintenance of Interferon-based therapy

Gliptins: risk of acute pancreatitis

Agomelatine: risk of dose-related hepatotoxicity and liver failure

Pradaxa: Boehringer Ingelheim discontinues RE-ALIGN trial in patients with artificial heart valves

Crohn’s disease: Ustekinumab induces clinical response

GS-7977 plus Pegylated Interferon and Ribavirin in patients with genotype 1 hepatitis C: 12-week regimen

Eylea for the treatment of wet age-related macular degeneration in Europe

VIEW 1 and VIEW 2 trials of Aflibercept injection for the treatment of patients with neovascular ( wet ) age-related macular degeneration: one-year results

Eliquis for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, approved in European Union

DIA3010 trial: Canagliflozin reduces A1C levels when added to antihyperglycemic therapy in older patients with type 2 diabetes and inadequate glycemic control

Tofacitinib, a JAK inhibitor: the first new oral DMARD for rheumatoid arthritis in more than 10 years

B-Long trial: positive results for ling-lasting recombinant Factor IX Fc fusion protein in hemophilia B

Lyxumia for treatment of diabetes mellitus type 2

Hepatitis C: Daclatasvir and GS-7977 have achieved sustained virologic response in 100% of genotype 1 and 91% of genotype 2 and 3 treatment-naïve patients in phase II study

European Union: Votrient has received marketing authorisation in the treatment of certain advanced soft tissue sarcoma subtypes

European Union: Jentadueto has received approval for the treatment of adults with diabetes mellitus type 2

FDA: a mesothelin-targeting antibody-drug conjugate has received orphan drug status for the treatment of mesothelioma

EU: refusal of the marketing authorisation for Elelyso because of the ten-year market exclusivity that had been granted for Vpriv

NICE recommends Xarelto, the only oral single-drug therapy for the treatment of deep vein thrombosis and prevention of recurrent DVT and pulmonary embolism

Truvada for pre-exposure prophylaxis to reduce risk of acquiring HIV

Myrbetriq is the first beta-3 adrenergic agonist indicated for the treatment of overactive bladder

Type 2 diabetes mellitus: improvement in albuminuria with Linagliptin in patients at high risk of declining renal function

Treatment for plague: FDA has approved Levaquin

Primary biliary cirrhosis: Bezafibrate

Interferons not useful in the secondary progressive multiple sclerosis

2012 - Gaucher disease type 1: Eliglustat has shown sustained or continued improvement in all endpoints at four-year follow-up

Inspra improves survival of stable patients with left ventricular systolic dysfunction

Telaprevir has shown efficacy among cirrhotic patients with genotype-1 chronic HCV compared to standard of care

Hemacord: FDA has approved first cord blood product

Enzyme replacement therapy with Elaprase for Hunter syndrome

Juvisync, first combination drug to treat type 2 diabetes and high cholesterol in one tablet

Selected risk information for Juvisync, a combination of Sitagliptin and Simvastatin

Sitagliptin is comparable to Glipizide in helping patients lower blood sugar

Zytiga for late-stage prostate cancer, FDA approves

TRITON-TIMI 38 trial: Prasugrel versus Clopidogrel in patients with acute coronary syndrome

Nulojix for preventing acute rejection in kidney transplant recipients

Hepatitis C infection: Telaprevir-based regimen acts faster and offers a stronger viral cure than standard treatment

Eylea for the treatment of patients with neovascular age-related macular degeneration

FDA has approved Rituximab to treat Wegener’s granulomatosis and microscopic polyangiitis

Metastatic melanoma: FDA has approved Yervoy

Fluzone influenza vaccine: VAERS reports of febrile seizures in children

Abnormal heart rhythms may be associated with use of Zofran

Major depressive disorder: FDA has approved Viibryd

FDA has approved Erbitux to treat late-stage head and neck cancer

Knee or hip replacement surgery: FDA has approved Xarelto to reduce risk of blood clots

Corifact for treatment of congenital factor XIII deficiency

Lynch syndrome: Acetylsalicylic acid reduces colorectal cancer rates by around 60%

Prasugrel versus Clopidogrel: non-fatal heart attacks occur less often in certain patients, but major bleeding events are more common

MHRA: the balance of risks and benefits of Reboxetine remains favourable

Follicular lymphoma: vaccine increases disease-free survival

FDA: revised dose limitation for Simvastatin when taken with Amiodarone

Saxagliptin added to Insulin significantly improves glycosylated hemoglobin levels in adults with type 2 diabetes compared to placebo added to Insulin

Idebenone improves sight for patients with Leber's hereditary optic neuropathy

Eylea for neovascular age-related macular degeneration in older people: FDA approved

Expression of dystrophin in Duchenne Muscular Dystrophy patients treated with Eteplirsen

Fasudil, a cardiovascular drug may offer new treatment for some difficult types of leukemia

Multiple sclerosis: Teriflunomide significantly reduces relapse rate, disability progression and disease activity

Raltegravir in combination therapy has shown efficacy and tolerability in adults with HIV-1 regardless of gender or race

Boceprevir: indications and usage for the treatment of chronic hepatitis C genotype 1 infection

Voriconazole and Anidulafungin combination therapy versus Voriconazole alone in invasive aspergillosis

FDA has approved Combivent Respimat inhalation spray for the treatment of patients with chronic obstructive pulmonary disease

Genotype 1 hepatitis C: BMS-790052 plus Peginterferon alfa and Ribavirin demonstrated up to 83% sustained virologic response 24 weeks post-treatment

Selumetinib in patients with KRAS-mutant non-small cell lung cancer

Metabolic therapy for autoimmune diseases: N-Acetylglucosamine suppresses multiple sclerosis attacks

Oral contraceptives containing Drospirenone linked to higher risk of venous thromboembolism than oral contraceptives containing Levonorgestrel

Zoledronic acid and risk of kidney failure: new contraindication in patients with osteoporosis

European Commission: Vibativ for treating adults with nosocomial pneumonia, including ventilator-associated pneumonia

Zytiga for treatment of metastatic castration-resistant prostate cancer in patients who have received prior chemotherapy containing Docetaxel

Long-term use of nonaspirin anti-inflammatory drugs linked to renal cell carcinoma

TNF-alpha blockers: warnings about infection with Legionella and Listeria bacteria

Vemurafenib in patients with previously untreated metastatic melanoma with the BRAFV600 mutation

Rare diseases: Firazyr, a self-administered subcutaneous treatment for acute hereditary angioedema

FDA has approved orphan drug Zactima for advanced medullary thyroid cancer

FDA approves Firazyr to treat acute attacks of hereditary angioedema

Stomach acid-reducing drugs: proton pump inhibitors may be dangerous

Relapsing-remitting multiple sclerosis: Daclizumab HYP reduces annualized relapse rate

FDA: Afinitor approved for progressive neuroendocrine tumors of pancreatic origin

Pagine successive [1] 2 3 4

Link

Specialità

Patologie

Patologie

© XAGENA 2010 - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati